靶向药物赫赛汀联合化疗治疗晚期乳腺癌的临床疗效  

Analysis of Inflammatory Factors and Clinical Efficacy of Targeted Drug Herceptin Combined with Chemotherapy in Advanced Breast Cancer

作　　者：董延琥[1] 罗代平[2] DONG Yanhu;LUO Daiping(Puyang People's Hospital,Puyang,457000)

机构地区：[1]河南省濮阳市人民医院,457000 [2]河南省濮阳市油田总医院,457001

出　　处：《实用癌症杂志》2019年第12期2008-2011,共4页The Practical Journal of Cancer

摘　　要：目的探讨靶向药物赫赛汀联合化疗治疗晚期乳腺癌的临床疗效及患者炎症因子水平变化。方法选取62例晚期乳腺癌患者,并按随机数字法均分为对照组(31例)和观察组(31例)。对照组采用化疗方案治疗,观察组采用靶向药物赫赛汀联合化疗方案治疗。采用酶联免疫吸附法检测患者治疗前、后血清炎症因子白介素-2(Interleukin-2,IL-2)、白介素-6(Interleukin-6,IL-6)、白介素-10(Interleukin-10,IL-10)、肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)及C反应蛋白(C reactiveprotein,CRP)水平,采用流式细胞仪分析患者的T淋巴细胞表达情况,并统计患者治疗有效率及不良反应发生率。结果观察组的临床有效率为90.32%(28/31),明显高于对照组临床有效率77.42%(24/31),差异有统计学意义(P<0.05)。治疗后,2组患者的血清炎症因子水平均明显改善,差异有统计学意义(P<0.05)。治疗后,对照组和观察组的IL-2、IL-6、IL-10、TNF-α、CRP水平差异均有统计学意义(P<0.05)。治疗后,对照组的CD8^+及CD4^+/CD8^+淋巴细胞水平无明显变化;观察组的CD3^+、CD4^+、CD8^+及CD4^+/CD8^+淋巴细胞水平均明显改善;组间对比,2组患者的CD8^+及CD4^+/CD8^+淋巴细胞水平差异有统计学意义(P<0.05)。观察组和对照组不良反应总发生率分别为16.13%(5/31)和25.81%(8/31),差异有统计学意义(P<0.05)。结论靶向药物赫赛汀联合化疗治疗晚期乳腺癌,能明显提高乳腺癌的治疗效果,保护患者机体免疫功能,调节患者炎性反应,值得临床借鉴推广。Objective To investigate the clinical efficacy of target drug herceptin combined with chemotherapy in the treatment of advanced breast cancer.Methods 62 patients with advanced breast cancer were selected and randomly divided into the control group(31 cases)and the observation group(31 cases).The control group was treated with chemotherapy.The observation group was treated with the targeted drug herceptin combined with chemotherapy.Serum levels of interleukin-2(IL-2),interleukin-2(IL-6),interleukin-10,Tumor necrosis factor-alpha(tnf-alpha)and C reactiveprotein(CRP)were detected before and after treatment.Flow cytometry was used to analyze the expression of T lymphocytes inpatients,and the effective rate of treatment and incidence of adverse reactions were calculated.Results The clinical efficacy of the observation group was 90.32%(28/31),which was significantly higher than that of the control group 77.42%(24/31),and the difference was statistically significant(P<0.05).After treatment,the levels of serum inflammatory factors in both groups were significantly improved,with statistically significant differences(P<0.05).After treatment,il-2 levels in the control and observation groups were(22.19±1.79)and(26.48±1.81)ng/ml,IL-6 levels were(52.18±4.7)and(37.19±4.37)mu/ml,IL-10 levels were(7.47±0.82)and(11.43±1.09)ng/ml,and tnf-alpha levels were(146.39±6.27)and(69.52±4.16)mu/ml,respectively.And CRP were(59.23±5.19)and(26.52±3.18)mg/l,respectively,with statistically significant differences(P<0.05).After treatment,there was no significant change in CD8^+and CD4^+/CD8^+lymphocyte levels in the control group.The levels of CD3^+,CD4^+,CD8^+and CD4^+/CD8^+lymphocytes in the observation group were significantly improved.There were significant differences in CD8^+and CD4^+/CD8^+lymphocyte levels between the 2 groups(P<0.05).The total incidence of adverse reactions in the observation group and the control group were 16.13%(5/31)and 25.81%(8/31),respectively,and the difference was statistically significant(P<0.05).Conclus

关 键 词：靶向药物 赫赛汀 化疗 晚期乳腺癌 炎症因子 

分 类 号：R737.9[医药卫生—肿瘤]